PE anti-human CD279 (PD-1) Antibody

Pricing & Availability
Clone
EH12.2H7 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1, PDCD1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_EH12dot2H7_PE_022508
PHA-stimulated (day-3) human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) PE (filled histogram) or mouse IgG1, κ PE (open histogram).
  • 1_EH12dot2H7_PE_022508
    PHA-stimulated (day-3) human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) PE (filled histogram) or mouse IgG1, κ PE (open histogram).
  • 2_EH12-2H7_PE_CD279_2_Antibody_103024
    Human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) PE and CD3 (clone UCHT1) PerCP/Cyanine5.5.
  • 3_2_Human_LN_IgD_PD-1
    Confocal image of human lymph node sample acquired using the IBEX method of highly multiplexed antibody-based imaging: IgD (blue) in Cycle 2, PD-1 (green) in Cycle 5. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
329905 25 tests 108€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
329906 100 tests 234€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The CD279 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
SB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References
  1. Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
  3. Velu V, et al. 2007. J. Virol. 81:5819. (FA)
  4. Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
  5. Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
  6. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
  7. Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
  8. Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
  9. Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
  10. Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
  11. Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
  12. Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
  13. Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
  14. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  15. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  16. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Shaw BI, et al. 2021. J Immunol. 206:1668. PubMed
  2. Li M, et al. 2021. J Clin Invest. 131:. PubMed
  3. Tocheva AS, et al. 2020. Curr Protoc Immunol. 130:e103. PubMed
  4. Asashima H, et al. 2022. J Clin Invest. 132: . PubMed
  5. Wei H, et al. 2022. Front Immunol. 13:1060695. PubMed
  6. Asashima H, et al. 2023. Cell Rep. 42:111895. PubMed
  7. Wu L, et al. 2023. Cell Rep Med. 4:100917. PubMed
  8. Saber MM, et al. 2023. J Immunol Res. 2023:4556586. PubMed
  9. Chen L, et al. 2023. Immunology. 169:204. PubMed
  10. Mohammad TAM, et al. 2023. Int J Rheum Dis. 26:740. PubMed
  11. Wu X, et al. 2023. iScience. 26:106559. PubMed
  12. Pedersen JM, et al. 2023. Arthritis Res Ther. 25:97. PubMed
  13. Jung MY, et al. 2022. Neurooncol Adv. 4:vdac017. PubMed
  14. Wang W, et al. 2022. World J Gastrointest Oncol. 14:1124. PubMed
  15. Rha MS, et al. 2021. Immunity. 54:44. PubMed
  16. Fujita T, et al. 2014. J Immunol. 193:5576. PubMed
  17. Chang W, et al. 2008. J Immunol. 181:6707. PubMed
  18. Wang F, et al. 2018. Oncogenesis. 7:41. PubMed
  19. Huang L, et al. 2018. Mol Med Rep. 18:77. PubMed
  20. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  21. Swadling L, et al. 2020. Cell Rep. 30:687. PubMed
  22. Zhou R, et al. 2020. Immunity. S1074-7613(20)30333-2.. PubMed
  23. Li H, et al. 2016. J Immunol. 196: 4064 - 4074. PubMed
  24. Diao B, et al. 2020. Front Immunol. 1.032638889. PubMed
  25. Lucas C, et al. 2020. Nature. 584:463. PubMed
  26. Chen M, et al. 2021. Cancers (Basel). 13:. PubMed
  27. Gao Y, et al. 2021. Oncogenesis. 10:62. PubMed
  28. Minns D, et al. 2021. Front Immunol. 12:633486. PubMed
  29. Rosskopf S, et al. 2016. Sci Rep. 6:31580. PubMed
  30. Karlsson H, et al. 2015. PLoS One. 10: 0144787. PubMed
  31. Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
  32. Zhu C, et al. 2012. J Clin Endocrinol Metab. 97:943. PubMed
  33. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
  34. Ma X et al. 2019. Cell Metab. 30(1):143-156 . PubMed
  35. Nduom E, et al. 2016. Neuro Oncology. 18: 195 - 205. PubMed
  36. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  37. Jutz S, et al. 2016. J Immunol Methods. 430:10-20. PubMed
  38. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  39. Pauthner M et al. 2017. Immunity. 46(6):1073-1088 . PubMed
  40. Suzuki M, et al. 2012. J Immunol. 189:2118. PubMed
  41. Bonifacius A, et al. 2021. Immunity. 54(2):340-354.e6. PubMed
  42. Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed
  43. Alishah K, et al. 2021. J Transl Med. 19:482. PubMed
  44. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  45. Raghuraman S, et al. 2012. J Infect Dis. 205:763. PubMed
  46. Wu L, et al. 2018. Oncol Lett. 15:9507. PubMed
  47. Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed
  48. Shen C, et al. 2021. Front Immunol. 12:680055. PubMed
  49. Song TZ, et al. 2021. Front Endocrinol (Lausanne). 12:745984. PubMed
  50. Chen W, et al. 2021. MAbs. 13:1914359. PubMed
  51. Vikkurthi R, et al. 2022. Nat Microbiol. 7:974. PubMed
  52. Chen Y, et al. 2022. Bioact Mater. 9:251. PubMed
  53. Huang RS, et al. 2021. Curr Protoc. 1:e246. PubMed
  54. Krishnan S, et al. 2021. Clin Exp Immunol. 203:458. PubMed
  55. OConnor RA, et al. 2021. OncoImmunology. 10(1):1940675. PubMed
  56. Colineau L, et al. 2015. PLoS One. 10: e0140978. PubMed
  57. Wang C, et al. 2020. Oncologist. 25:382. PubMed
  58. Kamiya T, et al. 2018. Blood Adv. 2:517. PubMed
  59. Good Z, et al. 2019. Nat Biotechnol. 37:259. PubMed
  60. Xu H, et al. 2013. J Leukoc Biol. 93:943. PubMed
  61. Li N, et al. 2020. Oncoimmunology. 9:1824643. PubMed
  62. Ling X, et al. 2022. STAR Protoc. 3:101321. PubMed
  63. Capuano C, et al. 2018. Front Immunol. 9:1031. PubMed
  64. Pombo C, et al. 2015. J Infect Dis. 12: 1376-1386. PubMed
  65. Saber MM, et al. 2022. Antibodies (Basel). 11:. PubMed
  66. Toor SM, et al. 2021. Vaccines (Basel). 9:. PubMed
  67. Shuwa HA, et al. 2021. Med. 2(6):720-735.e4. PubMed
  68. Radziewicz H, et al. 2010. J Immunol. 184:2410. PubMed
  69. Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed
  70. Matsuyama H, et al. 2019. Sci Rep. 9:13181. PubMed
  71. Xu Y, et al. 2013. J Virol. 87:3760. PubMed
  72. Richter M, et al. 2016. Mol Ther Methods Clin Dev. 5:16013. PubMed
  73. Eriksen LL, et al. 2021. PLoS One. 16:e0255574. PubMed
  74. Ukita M, et al. 2022. JCI Insight. 7:. PubMed
  75. Wadley AJ, et al. 2020. Brain Behav Immun Health. 3:100049. PubMed
  76. Zheng L, et al. 2020. Clin Cancer Res. 26:3694. PubMed
  77. Beyer M, et al. 2016. Nat Immunol. 17:593-603. PubMed
  78. Wang B, et al. 2018. Mol Ther Nucleic Acids. 0.548611111. PubMed
  79. Vojnov L, et al. 2010. J Virol. 84:753. PubMed
  80. Shen C, et al. 2021. BMC Med. 19:283. PubMed
  81. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  82. Zhang C, et al. 2020. Front Oncol. 0.944444444. PubMed
  83. Schumann K, et al. 2015. Proc Natl Acad Sci U S A. 112: 10437-10442. PubMed
  84. Li B, et al. 2019. Oncogenesis. 8:17. PubMed
  85. Cortés–Rubio CN, et al. 2019. Clin Epigenetics. 11:134. PubMed
RRID
AB_940481 (BioLegend Cat. No. 329905)
AB_940481 (BioLegend Cat. No. 329906)

Antigen Details

Structure
Immunoglobulin superfamily
Distribution

Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells

Ligand/Receptor
B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Gene ID
5133 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Other Formats

View All CD279 Reagents Request Custom Conjugation
Description Clone Applications
Brilliant Violet 421™ anti-human CD279 (PD-1) EH12.2H7 FC
Purified anti-human CD279 (PD-1) EH12.2H7 FC,Block,IHC-F
FITC anti-human CD279 (PD-1) EH12.2H7 FC
PE anti-human CD279 (PD-1) EH12.2H7 FC,SB
APC anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 647 anti-human CD279 (PD-1) EH12.2H7 FC
PerCP/Cyanine5.5 anti-human CD279 (PD-1) EH12.2H7 FC
APC/Cyanine7 anti-human CD279 (PD-1) EH12.2H7 FC
Pacific Blue™ anti-human CD279 (PD-1) EH12.2H7 FC
PE/Cyanine7 anti-human CD279 (PD-1) EH12.2H7 FC
Purified anti-human CD279 (PD-1) (Maxpar® Ready) EH12.2H7 FC,CyTOF®
Brilliant Violet 605™ anti-human CD279 (PD-1) EH12.2H7 FC
Ultra-LEAF™ Purified anti-human CD279 (PD-1) EH12.2H7 FC,Block,IHC-F
Brilliant Violet 711™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 785™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 510™ anti-human CD279 (PD-1) EH12.2H7 FC
Biotin anti-human CD279 (PD-1) EH12.2H7 FC
PE/Dazzle™ 594 anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 488 anti-human CD279 (PD-1) EH12.2H7 FC
PerCP anti-human CD279 (PD-1) EH12.2H7 FC
GoInVivo™ Purified anti-human CD279 (PD-1) EH12.2H7 FC,Block,IHC
Brilliant Violet 650™ anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 700 anti-human CD279 (PD-1) EH12.2H7 FC
APC/Fire™ 750 anti-human CD279 (PD-1) EH12.2H7 FC
TotalSeq™-A0088 anti-human CD279 (PD-1) EH12.2H7 PG
TotalSeq™-B0088 anti-human CD279 (PD-1) EH12.2H7 PG
TotalSeq™-C0088 anti-human CD279 (PD-1) EH12.2H7 PG
Brilliant Violet 750™ anti-human CD279 (PD-1) EH12.2H7 FC
TotalSeq™-D0088 anti-human CD279 (PD-1) EH12.2H7 PG
PE/Fire™ 640 anti-human CD279 (PD-1) EH12.2H7 FC
PE/Cyanine5 anti-human CD279 (PD-1) EH12.2H7 FC
PE/Fire™ 744 anti-human CD279 (PD-1) EH12.2H7 FC
Spark Red™ 718 anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 570™ anti-human CD279 (PD-1) EH12.2H7 FC
Go To Top Version: 3    Revision Date: 04/19/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account